Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of liberal preoperative clear fluid fasting regimens on the risk of pulmonary aspiration in children (EUROFAST). Response to Br J Anaesth 2025; 135: 1114-5.

British journal of anaesthesia·2025
Same author

The role of dynamic monitoring of plasma cell-free DNA methylation in predicting pathological response in resectable stage IIB-IIIB non-small cell lung cancer: biomarker analyses from a prospective phase II trial.

BMC medicine·2025
Same author

Epidemiology of patients with moderate-to-severe SLE in Sweden.

Lupus science & medicine·2025
Same author

Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy Alone.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2025
Same author

Multi‑omics analysis identifies different molecular subtypes with unique outcomes in early-stage poorly differentiated lung adenocarcinoma.

Molecular cancer·2025
Same author

Randomized Trial of Very Early Medication Abortion.

The New England journal of medicine·2024

Related Experiment Video

Updated: Jul 3, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K

A Novel Risk Score (P-score) Based on a Three-Gene Signature, for Estimating the Risk of Prostate Cancer-Specific

Fabian Söderdahl1, Li-Di Xu2, Johan Bring1

  • 1Statisticon AB, Uppsala, Sweden.

Research and Reports in Urology
|May 19, 2022
PubMed
Summary
This summary is machine-generated.

A new P-score algorithm integrating a three-gene signature and clinical data predicts prostate cancer (PCa) death risk. This tool aids in distinguishing PCa patient outcomes for improved treatment decisions.

Keywords:
Prostatypebiomarkerbiopsygenetic testingprognosisprostate cancer

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Related Experiment Videos

Last Updated: Jul 3, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Area of Science:

  • Oncology
  • Genetics
  • Biostatistics

Background:

  • Prostate cancer (PCa) remains a significant cause of mortality.
  • Accurate risk stratification is crucial for effective PCa management.
  • Existing risk assessment tools may require enhancement for improved prediction accuracy.

Purpose of the Study:

  • To develop and validate the P-score, a novel risk prediction algorithm for PCa.
  • The P-score integrates a three-gene signature with clinicopathological parameters.
  • To predict the risk of death from prostate cancer in a retrospective cohort.

Main Methods:

  • A cohort of 591 PCa patients diagnosed between 2003-2008 in Stockholm was analyzed.
  • A three-gene signature (IGFBP3, F3, VGLL3) expression was measured from diagnostic core needle biopsies (CNB).
  • A point-based scoring system using a Fine-Gray competing risk model was developed, incorporating the gene signature, PSA, Gleason score, and tumor stage.

Main Results:

  • The P-score, ranging from 0 to 15, demonstrated a significant association with PCa-specific mortality (HR 1.39 per unit increase, p < 0.001).
  • The P-score exhibited superior predictive performance compared to D'Amico and NCCN risk stratification systems (concordance index).
  • Both the P-score and the gene signature effectively stratified patients into distinct risk groups, as shown by cumulative incidence functions.

Conclusions:

  • The P-score is a validated risk stratification system for newly diagnosed PCa patients.
  • The P-score integrates a three-gene signature from CNB tissue with clinical data.
  • This tool offers valuable decision support for differentiating PCa patient outcomes and optimizing treatment strategies.